Qi Y Chen

US Patent:

7812038, Oct 12, 2010

Filed:

Jun 14, 2005

Appl. No.:

11/152695

Inventors:

Ronald J. Biediger - Houston TX, US
Qi Chen - Carmel IN, US
E. Radford Decker - Houston TX, US
George W. Holland - Houston TX, US
Jamal M. Kassir - Stafford TX, US
Wen Li - Pearland TX, US
Robert V. Market - Pearland TX, US
Ian L. Scott - Delanson NY, US
Chengde Wu - Pearland TX, US
Jian Li - The Woodlands TX, US

Assignee:

Encysive Pharmaceuticals, Inc. - New York NY

International Classification:

A61K 31/4412

US Classification:

514352, 514345, 514349, 546183, 546290, 546296, 546297

Abstract:

A method for the inhibition of the binding of αβintegrin to its receptors, for example VCAM-1 (vascular cell adhesion molecule-1) and fibronectin; compounds that inhibit this binding; pharmaceutically active compositions comprising such compounds; and to the use of such compounds either a above, or in formulations for the control or prevention of diseases states in which αβis involved.

US Patent:

8138215, Mar 20, 2012

Filed:

May 14, 2010

Appl. No.:

12/780415

Inventors:

Omar D. Lopez - Wallingford CT, US
Qi Chen - Norwalk CT, US
Makonen Belema - North Haven CT, US

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

A61K 31/4174
C07D 233/64

US Classification:

514397, 5483131

Abstract:

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

US Patent:

8377980, Feb 19, 2013

Filed:

Dec 1, 2010

Appl. No.:

12/957512

Inventors:

Makonen Belema - North Haven CT, US
Jeffrey Lee Romine - Meriden CT, US
Van N. Nguyen - Meriden CT, US
Gan Wang - Wallingford CT, US
Omar D. Lopez - Wallingford CT, US
Denis R. St. Laurent - Newington CT, US
Qi Chen - Stamford CT, US
John A. Bender - Middletown CT, US
Zhong Yang - Southington CT, US
Piyasena Hewawasam - Middletown CT, US
Ningning Xu - Wallingford CT, US
Nicholas A. Meanwell - East Hampton CT, US
John A. Easter - East Hampton CT, US
Michael J. Smith - Somerset NJ, US

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

A61K 31/4178
C07D 233/64

US Classification:

514397, 5483131

Abstract:

The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

US Patent:

20040063955, Apr 1, 2004

Filed:

Oct 9, 2001

Appl. No.:

09/973142

Inventors:

Ronald Biediger - Houston TX, US
Qi Chen - Carmel IN, US
E. Decker - Houston TX, US
George Holland - Houston TX, US
Jamal Kassir - Stafford TX, US
Wen Li - Pearland TX, US
Robert Market - Pearland TX, US
Ian Scott - Delanson NY, US
Chengde Wu - Pearland TX, US
Jian Li - The Woodlands TX, US

International Classification:

C07D211/40
C07D211/56
C07D211/54

US Classification:

546/216000, 546/223000, 546/237000

Abstract:

A method for the inhibition of the binding of integrin to its receptors, for example VCAM-1 (vascular cell adhesion molecule-1) and fibronectin; compounds that inhibit this binding; pharmaceutically active compositions comprising such compounds; and to the use of such compounds either a above, or in formulations for the control or prevention of diseases states in which is involved.

US Patent:

20100249190, Sep 30, 2010

Filed:

Mar 25, 2010

Appl. No.:

12/731935

Inventors:

Omar D. Lopez - Wallingford CT, US
Qi Chen - Norwalk CT, US
Makonen Belema - North Haven CT, US
Lawrence G. Hamann - North Grafton MA, US

International Classification:

A61K 31/454
C07D 403/14
A61K 31/4178
A61P 31/14
C07D 401/14
C07D 413/14
A61K 31/422

US Classification:

514326, 5483131, 514397, 546210, 548236, 514374

Abstract:

This disclosure concerns novel compounds of Formula (I) as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds.

US Patent:

20110274648, Nov 10, 2011

Filed:

Nov 4, 2010

Appl. No.:

12/939778

Inventors:

Rico Lavoie - Candiac, CA
John A. Bender - Middletown CT, US
Zhong Yang - Southington CT, US
Makonen Belema - North Haven CT, US
Omar D. Lopez - Wallingford CT, US
Qi Chen - Stamford CT, US
Gan Wang - Wallingford CT, US
Piyasena Hewawasam - Middletown CT, US

International Classification:

A61K 31/4184
C07D 401/14
A61K 31/4545
A61K 31/437
A61K 31/4985
A61K 31/4178
A61K 31/4709
C07D 471/04
A61K 31/4375
C07D 413/14
A61K 31/5377
A61K 38/21
A61K 31/7056
A61K 38/20
A61K 31/713
A61P 31/14
C07D 403/14

US Classification:

424 852, 5483054, 514394, 5483061, 546187, 514316, 546118, 514303, 544350, 514249, 5483131, 514397, 546173, 514306, 544353, 546122, 514300, 544 79, 5142322, 424 854, 514 43, 424 857, 514 44 A

Abstract:

The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

US Patent:

20110281910, Nov 17, 2011

Filed:

Nov 9, 2010

Appl. No.:

12/942183

Inventors:

Rico Lavoie - Candiac, CA
John A. Bender - Middletown CT, US
Jeffrey Lee Romine - Meriden CT, US
Edward H. Ruediger - Greenfield Park, CA
Carol Bachand - Candiac, CA
Omar D. Lopez - Wallingford CT, US
Qi Chen - Stamford CT, US
Makonen Belema - North Haven CT, US
John F. Kadow - Wallingford CT, US
Lawrence G. Hamann - North Grafton MA, US

International Classification:

A61K 31/4178
C07D 417/14
C07D 413/14
C07D 403/14
A61P 31/14
C07D 407/14
A61K 31/427
A61K 31/422
A61K 31/4545
C07D 409/14
C07D 401/14

US Classification:

514316, 5483131, 548204, 548236, 546187, 514397, 514365, 514374

Abstract:

This disclosure concerns novel compounds of Formula (I) or as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds.

US Patent:

20120195857, Aug 2, 2012

Filed:

Aug 4, 2011

Appl. No.:

13/198529

Inventors:

Makonen Belema - North Haven CT, US
Pothukanuri Srinivasu - Bangalore, IN
John A. Bender - Middletown CT, US
Omar D. Lopez - Wallingford CT, US
Qi Chen - Stamford CT, US
Richard A. Rampulla - Flemington NJ, US
Samayamunthula Venkata Satya Arun Kumar Gupta - Bangalore, IN
Nicholas A. Meanwell - East Hampton CT, US

International Classification:

A61K 31/4178
C07D 413/14
A61K 31/422
C07D 417/14
A61K 31/433
A61P 31/14
A61K 31/5025
A61K 31/7056
A61K 38/21
A61K 38/48
A61K 38/44
A61K 38/46
C07D 403/14
C07D 487/04

US Classification:

424 857, 5483131, 514397, 5483121, 548235, 514374, 548134, 514362, 544349, 514249, 514 43, 424 854, 424 9467, 424 9464, 424 945, 424 946, 514 43

Abstract:

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.